[
    {
        "question_id": "1_B_2222",
        "new_question_id": "4259",
        "question_type": "0",
        "category": "11",
        "concept_id_link": "0",
        "notes_id_link": "1_1713",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Give further Magnesium Sulphate",
            "Give further labetalol",
            "Emergency caesarian section",
            "Foetal scalp pH testing",
            "Induce labour<br />",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 26-year-old woman was admitted at 34 weeks gestation with a blood pressure of 175/105 mmHg and 3+ proteinuria.  She is commenced on magnesium sulphate and labetalol.  She complains of reduced foetal movements.   A cardiotocogram shows late decelerations and a foetal heart rate of 90 beats/minute.  What should be the next step in the management?",
            "",
            ""
        ],
        "answers": [
            "3",
            "",
            ""
        ],
        "notes": [
            "A diagnosis of pre-eclampsia can be made due to the heavy proteinuria and hypertension.  Magnesium sulphate is given to reduce the risk of development of eclampsia, and labetalol is given to control the blood pressure.  Late decelerations and foetal bradycardia on cardiotocography (CTG)  is a worrying sign and would justify an emergency caesarian section.  Induction would be inappropriate with an abnormal CTG.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 26-year-old woman was admitted at 34 weeks gestation with a blood pressure of 175/105 mmHg and 3+ proteinuria.  She is commenced on magnesium sulphate and labetalol.  She complains of reduced foetal movements.   A cardiotocogram shows late decelerations and a foetal heart rate of 90 beats/minute.  What should be the next step in the management?",
        "correct_answer": "3",
        "question_notes": "A diagnosis of pre-eclampsia can be made due to the heavy proteinuria and hypertension.  Magnesium sulphate is given to reduce the risk of development of eclampsia, and labetalol is given to control the blood pressure.  Late decelerations and foetal bradycardia on cardiotocography (CTG)  is a worrying sign and would justify an emergency caesarian section.  Induction would be inappropriate with an abnormal CTG.",
        "answer_order": "3",
        "answer": "3",
        "title": "Cardiotocography",
        "body": "Cardiotocography (CTG) records pressure changes in the uterus using internal or external pressure transducers<br /><br />The normal fetal heart rate varies between 100-160 / min<br /><br /><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th><b>Feature</b></th><th><b>Description</b></th><th><b>Causes</b></th></tr></thead><tbody><tr><td>Baseline bradycardia</td><td>Heart rate < 100 /min</td><td>Increased fetal vagal tone, maternal beta-blocker use</td></tr><tr><td>Baseline tachycardia</td><td>Heart rate > 160 /min</td><td>Maternal pyrexia, chorioamnionitis, hypoxia, prematurity</td></tr><tr><td>Loss of baseline variability</td><td>< 5 beats / min</td><td>Prematurity, hypoxia</td></tr><tr><td>Early deceleration</td><td>Deceleration of the heart rate which commences with the onset of a contraction and returns to normal on completion of the contraction</td><td>Usually an innocuous feature and indicates head compression</td></tr><tr><td>Late deceleration</td><td>Deceleration of the heart rate which lags the onset of a contraction and does not returns to normal until after 30 seconds following the end of the contraction</td><td>Indicates fetal distress e.g. asphyxia or placental insufficiency</td></tr><tr><td>Variable decelerations</td><td>Independent of contractions</td><td>May indicate cord compression</td></tr></tbody></table></div>",
        "notes_hash": "9598f06edf875e44bf6f5fdbfd1fc7b3",
        "knowledge_graph_node_id_link": 0,
        "concept": "",
        "concept_percentile": 0,
        "concept_colour": "",
        "number_attempts": "5795",
        "up_votes": "42",
        "down_votes": "4",
        "column_array": [
            0,
            "99",
            "41",
            "5284",
            "98",
            "273",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "<table style='width:100%'><tr><td>NICE</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_150\" data-linkid=\"150\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_150\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">4</span><button type=\"button\" style=\"\" id=\"link_dislike_150\" data-linkid=\"150\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_150\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">6</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.nice.org.uk/guidance/cg190/resources/interpretation-of-cardiotocograph-traces-table-248732173\">Interpretation of cardiotocograph traces</a></td></tr></table><br><br><table style='width:100%'><tr><td>Perinatology.com</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1159\" data-linkid=\"1159\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_1159\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">7</span><button type=\"button\" style=\"\" id=\"link_dislike_1159\" data-linkid=\"1159\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_1159\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">3</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"http://perinatology.com/Fetal%20Monitoring/Intrapartum%20Monitoring.htm\">CTG interpretation</a></td></tr></table><br><br><table style='width:100%'><tr><td>NICE</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_377\" data-linkid=\"377\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_377\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">3</span><button type=\"button\" style=\"\" id=\"link_dislike_377\" data-linkid=\"377\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_377\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">1</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.nice.org.uk/guidance/cg190/chapter/1-Recommendations\">2014 Intrapartum care for healthy women and babies</a></td></tr></table><br><br><table style='width:100%'><tr><td>Geeky medics</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1166\" data-linkid=\"1166\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_1166\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">20</span><button type=\"button\" style=\"\" id=\"link_dislike_1166\" data-linkid=\"1166\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_1166\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">3</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://geekymedics.com/how-to-read-a-ctg/\">How to read a CTG</a></td></tr></table>",
        "media": "",
        "comment_count": 3,
        "concepts_for_notes": [],
        "optimisation_reason": ""
    },
    {
        "question_id": "1_B_9848",
        "new_question_id": "1894",
        "question_type": "0",
        "category": "9",
        "concept_id_link": "8279",
        "notes_id_link": "1_1237",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Postural hypotension",
            "Diarrhoea",
            "Myoclonic jerks",
            "Hallucinations",
            "Seizures",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A patient reports feeling unwell after suddenly stopping paroxetine. Which one of the following symptoms is most consistent with selective serotonin reuptake inhibitor discontinuation syndrome?",
            "",
            ""
        ],
        "answers": [
            "2",
            "",
            ""
        ],
        "notes": [
            "Selective serotonin reuptake inhibitor discontinuation syndrome can present with a wide variety of symptoms including diarrhoea, vomiting and abdominal pain.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A patient reports feeling unwell after suddenly stopping paroxetine. Which one of the following symptoms is most consistent with selective serotonin reuptake inhibitor discontinuation syndrome?",
        "correct_answer": "2",
        "question_notes": "Selective serotonin reuptake inhibitor discontinuation syndrome can present with a wide variety of symptoms including diarrhoea, vomiting and abdominal pain.",
        "answer_order": "2",
        "answer": "2",
        "title": "Selective serotonin reuptake inhibitors",
        "body": "Selective serotonin reuptake inhibitors (SSRIs) are considered first-line treatment for the majority of patients with depression. <br /><ul><li>citalopram (although see below re: QT interval) and fluoxetine are currently the preferred SSRIs</li><li><span class=\"concept\" data-cid=\"2415\">sertraline is useful post myocardial infarction</span> as there is more evidence for its safe use in this situation than other antidepressants</li><li>SSRIs should be used with caution in <span class=\"concept\" data-cid=\"243\">children and adolescents. Fluoxetine is the drug of choice</span> when an antidepressant is indicated</li></ul><br />Adverse effects<br /><ul><li>gastrointestinal symptoms are the most common side-effect</li><li>there is an increased risk of gastrointestinal bleeding in patients taking SSRIs. A proton pump inhibitor should be prescribed if a patient is also taking a NSAID</li><li>patients should be counselled to be vigilant for increased anxiety and agitation after starting a SSRI</li><li>fluoxetine and paroxetine have a higher propensity for drug interactions</li></ul><br /><span class=\"concept\" data-cid=\"9510\">Citalopram and the QT interval</span><br /><ul><li>the Medicines and Healthcare products Regulatory Agency (MHRA) released a warning on the use of citalopram in 2011</li><li>it advised that citalopram and escitalopram are associated with dose-dependent QT interval prolongation and should not be used in those with: congenital long QT syndrome; known pre-existing QT interval prolongation; or in combination with other medicines that prolong the QT interval</li><li>the maximum daily dose is now 40 mg for adults; 20 mg for patients older than 65 years; and 20 mg for those with hepatic impairment</li></ul><br />Interactions<br /><ul><li><span class=\"concept\" data-cid=\"242\">NSAIDs</span>: NICE guidelines advise 'do not normally offer SSRIs', but if given co-prescribe a proton pump inhibitor</li><li><span class=\"concept\" data-cid=\"2414\">warfarin</span> / heparin: NICE guidelines recommend avoiding SSRIs and considering mirtazapine</li><li>aspirin</li><li><span class=\"concept\" data-cid=\"8281\">triptans</span> - increased risk of serotonin syndrome</li><li><span class=\"concept\" data-cid=\"1140\">monoamine oxidase inhibitors (MAOIs)</span> - increased risk of serotonin syndrome</li></ul><br />Following the initiation of antidepressant therapy patients should normally be reviewed by a doctor after 2 weeks. For <span class=\"concept\" data-cid=\"11945\">patients under the age of 25 years or at increased risk of suicide should be reviewed after 1 week</span>. If a patient makes a good response to antidepressant therapy they should continue on treatment for at least <span class=\"concept\" data-cid=\"1143\">6 months</span> after remission as this reduces the risk of relapse. <br /><br />When stopping a SSRI the dose should be gradually reduced over a <span class=\"concept\" data-cid=\"8280\">4 week</span> period (this is not necessary with fluoxetine). <span class=\"concept\" data-cid=\"241\">Paroxetine has a higher incidence of discontinuation symptoms</span>.<br /><br /><span class=\"concept\" data-cid=\"1144\">Discontinuation symptoms</span><br /><ul><li>increased mood change</li><li>restlessness</li><li>difficulty sleeping</li><li>unsteadiness</li><li>sweating</li><li><span class=\"concept\" data-cid=\"8279\">gastrointestinal symptoms: pain, cramping, diarrhoea, vomiting</span></li><li>paraesthesia</li></ul><br />SSRIs and pregnancy<br />    -    BNF says to weigh up benefits and risk when deciding whether to use in pregnancy.<br />    -    Use during the first trimester gives a small increased risk of congenital heart defects<br />    -    Use during the third trimester can result in <span class=\"concept\" data-cid=\"2681\">persistent pulmonary hypertension</span> of the newborn<br />    -    <span class=\"concept\" data-cid=\"2684\">Paroxetine has an increased risk of congenital malformations</span>, particularly in the first trimester",
        "notes_hash": "68dbd8a42b65755d61d01a8b61c29a88",
        "knowledge_graph_node_id_link": 10859,
        "concept": "Gastrointestinal side-effects such as diarrhoea are seen in SSRI discontinuation syndrome",
        "concept_percentile": "84",
        "concept_colour": "rgb(81,255,0)",
        "number_attempts": "3961",
        "up_votes": "4",
        "down_votes": "5",
        "column_array": [
            0,
            "352",
            "2399",
            "561",
            "316",
            "333",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "<table style='width:100%'><tr><td>NICE</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_803\" data-linkid=\"803\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_803\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">36</span><button type=\"button\" style=\"\" id=\"link_dislike_803\" data-linkid=\"803\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_803\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">41</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.nice.org.uk/guidance/ng222/chapter/Recommendations\">2022 Depression in adults: treatment and management</a></td></tr></table>",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/T25jvLC6X0w\" data-description=\"Antidepressants\" data-upvotes=\"9\" data-downvotes=\"3\" data-media=\"631\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/T25jvLC6X0w/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/T25jvLC6X0w\" data-description=\"Antidepressants\" data-upvotes=\"9\" data-downvotes=\"3\" data-media=\"631\">Antidepressants</a></td></tr><tr><td><span ><small>Speed Pharmacology - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1082\" data-mediaid=\"1082\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_1082\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">9</span><button type=\"button\" style=\"\" id=\"media_dislike_1082\" data-mediaid=\"1082\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_1082\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">3</span></td></tr><tr><td>&nbsp;</td></tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/4X5nqkEBmTo\" data-description=\"Antidepressants Pharmacology\" data-upvotes=\"3\" data-downvotes=\"5\" data-media=\"313\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/4X5nqkEBmTo/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/4X5nqkEBmTo\" data-description=\"Antidepressants Pharmacology\" data-upvotes=\"3\" data-downvotes=\"5\" data-media=\"313\">Antidepressants Pharmacology</a></td></tr><tr><td><span ><small>Soton Brain Hub - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_533\" data-mediaid=\"533\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_533\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">3</span><button type=\"button\" style=\"\" id=\"media_dislike_533\" data-mediaid=\"533\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_533\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">5</span></td></tr></table>",
        "comment_count": 0,
        "concepts_for_notes": {
            "242": {
                "concept_text": "SSRI + NSAID = GI bleeding risk - give a PPI",
                "concept_percentile": "78"
            },
            "243": {
                "concept_text": "Fluoxetine is the SSRI of choice in children and adolescents",
                "concept_percentile": "85"
            },
            "1140": {
                "concept_text": "SSRIs and MAOIs should never be combined as there is a risk of serotonin syndrome",
                "concept_percentile": "94"
            },
            "1143": {
                "concept_text": "Antidepressants should be continued for at least 6 months after remission of symptoms to decrease risk of relapse",
                "concept_percentile": "55"
            },
            "1144": {
                "concept_text": "Dizziness, electric shock sensations and anxiety are symptoms of SSRI discontinuation syndrome\r\n",
                "concept_percentile": "96"
            },
            "2415": {
                "concept_text": "Sertraline is the SSRI of choice post myocardial infarction",
                "concept_percentile": "76"
            },
            "2684": {
                "concept_text": "Paroxetine use in pregnancy - can lead to increased risk of congenital malformations",
                "concept_percentile": "69"
            },
            "8279": {
                "concept_text": "Gastrointestinal side-effects such as diarrhoea are seen in SSRI discontinuation syndrome",
                "concept_percentile": "84"
            },
            "8281": {
                "concept_text": "Triptans should be avoided in patients taking a SSRI",
                "concept_percentile": "85"
            },
            "9510": {
                "concept_text": "Citalopram is the most likely SSRI to lead to QT prolongation and Torsades de pointes",
                "concept_percentile": "96"
            },
            "11945": {
                "concept_text": "Patients \u2264  25 years who have been started on an SSRI should be reviewed after 1 week",
                "concept_percentile": "96"
            }
        },
        "optimisation_reason": ""
    },
    {
        "question_id": "4972_B_135",
        "new_question_id": "15582",
        "question_type": "0",
        "category": "5",
        "concept_id_link": "3914",
        "notes_id_link": "1_2205",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Allopurinol",
            "Dexamethasone",
            "Loop diuretics",
            "Radiotherapy",
            "Thiazide-like diuretics",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 35-year-old man has been recently diagnosed with Hodgkin's lymphoma. He started the first day of his chemotherapy yesterday, but since then has not been feeling well. The FY2 on the ward checked his U&E and found some abnormalities including hyperkalaemia, hyperphosphataemia and hypocalcaemia. Which of the following is used as prophylaxis against the complication this man has suffered?",
            "",
            ""
        ],
        "answers": [
            "1",
            "0",
            "0"
        ],
        "notes": [
            "The history above is clearly that of tumour lysis syndrome- person with lymphoma being started on chemotherapy with high potassium, high phosphate, and low calcium. The most commonly used prophylaxis is allopurinol (either IV or oral), with rasburicase an alternative. Diuretics are not used for many reasons, including the fact they will worsen any acute kidney injury. Steroids and radiotherapy are actually rare causes of tumour lysis syndrome.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 35-year-old man has been recently diagnosed with Hodgkin's lymphoma. He started the first day of his chemotherapy yesterday, but since then has not been feeling well. The FY2 on the ward checked his U&E and found some abnormalities including hyperkalaemia, hyperphosphataemia and hypocalcaemia. Which of the following is used as prophylaxis against the complication this man has suffered?",
        "correct_answer": "1",
        "question_notes": "The history above is clearly that of tumour lysis syndrome- person with lymphoma being started on chemotherapy with high potassium, high phosphate, and low calcium. The most commonly used prophylaxis is allopurinol (either IV or oral), with rasburicase an alternative. Diuretics are not used for many reasons, including the fact they will worsen any acute kidney injury. Steroids and radiotherapy are actually rare causes of tumour lysis syndrome.",
        "answer_order": "1",
        "answer": "1",
        "title": "Tumour lysis syndrome",
        "body": "Tumour lysis syndrome (TLS) is a potentially deadly condition related to the treatment of high-grade lymphomas and leukaemias.  It can occur in the absence of chemotherapy but is usually triggered by the introduction of combination <span class=\"concept\" data-cid=\"11871\">chemotherapy</span>.  On occasion, it can occur with steroid treatment alone.  Awareness of the condition is critical as prophylactic medication can be given to prevent the potentially deadly effects of tumour cell lysis.  <br /><br />TLS occurs from the breakdown of the tumour cells and the subsequent release of chemicals from the cell.  It leads to <span class=\"concept\" data-cid=\"3914\">a high potassium and high phosphate level in the presence of a low calcium</span>. It should be suspected in any patient presenting with an acute kidney injury in the presence of a high phosphate and high uric acid level. <br /><br />Prevention<br /><ul><li>IV fluids</li><li>patients are higher risk should receive either <span class=\"concept\" data-cid=\"1736\">allopurinol or rasburicase</span> </li><li>rasburicase<ul><li>a <span class=\"concept\" data-cid=\"534\">recombinant version of urate oxidase, an enzyme that metabolizes uric acid to allantoin</span>. Allantoin is much more water-soluble than uric acid and is, therefore, more easily excreted by the kidneys</li><li><span class=\"concept\" data-cid=\"12119\">generally preferred now for patients at a higher risk of developing TLS</span></li></ul></li><li>allopurinol<ul><li>generally used for patients in lower-risk groups</li></ul></li><li><span class=\"concept\" data-cid=\"10594\">rasburicase and allopurinol should not be given together</span> in the management of tumour lysis syndrome as this reduces the effect of rasburicase</li></ul><br /><br />From 2004 TLS has been graded using the Cairo-Bishop scoring system - <br />Laboratory tumor lysis syndrome: abnormality in two or more of the following, occurring within three days before or seven days after chemotherapy.<br /><ul><li>uric acid > 475umol/l or 25% increase</li><li>potassium > 6 mmol/l or 25% increase</li><li>phosphate > 1.125mmol/l or 25% increase</li><li>calcium < 1.75mmol/l or 25% decrease</li></ul><br />Clinical tumor lysis syndrome: laboratory <span class=\"concept\" data-cid=\"4221\">tumour lysis syndrome plus one or more of the following</span>:<br /><ul><li>increased serum creatinine (1.5 times upper limit of normal)</li><li>cardiac arrhythmia or sudden death</li><li>seizure</li></ul>",
        "notes_hash": "053a9e3500811be7f38d1cf6c1d8d821",
        "knowledge_graph_node_id_link": 0,
        "concept": "High potassium, high phosphate, and low calcium are the metabolic abnormalities in tumour lysis syndrome",
        "concept_percentile": "87",
        "concept_colour": "rgb(66,255,0)",
        "number_attempts": "4583",
        "up_votes": "53",
        "down_votes": "12",
        "column_array": [
            0,
            "3134",
            "512",
            "432",
            "66",
            "439",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/yPLzcb9fM60\" data-description=\"Tumour lysis syndrom\" data-upvotes=\"4\" data-downvotes=\"1\" data-media=\"1173\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/yPLzcb9fM60/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/yPLzcb9fM60\" data-description=\"Tumour lysis syndrom\" data-upvotes=\"4\" data-downvotes=\"1\" data-media=\"1173\">Tumour lysis syndrom</a></td></tr><tr><td><span ><small>Armando Hasudungan - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2026\" data-mediaid=\"2026\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_2026\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">4</span><button type=\"button\" style=\"\" id=\"media_dislike_2026\" data-mediaid=\"2026\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_2026\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1</span></td></tr><tr><td>&nbsp;</td></tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/p9wTY_oui6c\" data-description=\"Tumour Lysis Syndrome in 3 Minutes\" data-upvotes=\"13\" data-downvotes=\"3\" data-media=\"1396\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/p9wTY_oui6c/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/p9wTY_oui6c\" data-description=\"Tumour Lysis Syndrome in 3 Minutes\" data-upvotes=\"13\" data-downvotes=\"3\" data-media=\"1396\">Tumour Lysis Syndrome in 3 Minutes</a></td></tr><tr><td><span ><small>Townsend Teaching - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2459\" data-mediaid=\"2459\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_2459\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">13</span><button type=\"button\" style=\"\" id=\"media_dislike_2459\" data-mediaid=\"2459\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_2459\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">3</span></td></tr><tr><td>&nbsp;</td></tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/v6VidGkd4XY\" data-description=\"Tumour Lysis Syndrome\" data-upvotes=\"0\" data-downvotes=\"1\" data-media=\"1224\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/v6VidGkd4XY/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/v6VidGkd4XY\" data-description=\"Tumour Lysis Syndrome\" data-upvotes=\"0\" data-downvotes=\"1\" data-media=\"1224\">Tumour Lysis Syndrome</a></td></tr><tr><td><span ><small>Oncology for Medical Students - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2140\" data-mediaid=\"2140\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_2140\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">0</span><button type=\"button\" style=\"\" id=\"media_dislike_2140\" data-mediaid=\"2140\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_2140\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1</span></td></tr></table>",
        "comment_count": 6,
        "concepts_for_notes": {
            "1736": {
                "concept_text": "Giving allopurinol or rasburicase prior to chemotherapy is a way to reduce the risk of developing tumour lysis syndrome",
                "concept_percentile": "83"
            },
            "3914": {
                "concept_text": "High potassium, high phosphate, and low calcium are the metabolic abnormalities in tumour lysis syndrome",
                "concept_percentile": "87"
            },
            "4221": {
                "concept_text": "To diagnose tumour lysis syndrome, you require either increased serum creatinine, a cardiac arrhythmia or a seizure to have occurred ",
                "concept_percentile": "99"
            }
        },
        "optimisation_reason": ""
    },
    {
        "question_id": "1_B_139",
        "new_question_id": "3110",
        "question_type": "0",
        "category": "2",
        "concept_id_link": "0",
        "notes_id_link": "1_1515",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Telogen effluvium",
            "Alopecia areata",
            "Tinea capitis",
            "Male-pattern baldness",
            "Discoid lupus erythematous",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 23-year-old man presents as he is concerned about recent hair loss. Examination reveals the following:<br /><br /><CENTER><table><tr><td align = 'left' colspan='2'><img class='ajaximage' src = 'https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/img001.jpg' /></td></tr><tr><td valign='top' align='left'></td><td align='right'></td></tr></table></CENTER><br />What is the most likely diagnosis?",
            "",
            ""
        ],
        "answers": [
            "2",
            "",
            ""
        ],
        "notes": [
            "The correct answer is <b>Alopecia areata</b>. This is an autoimmune condition characterised by well-demarcated, smooth, round or oval patches of hair loss without any visible inflammation, scaling, or scarring of the underlying skin. The image shows a classic presentation of alopecia areata with a discrete, circular area of complete hair loss on the scalp. The skin within the affected area appears normal and smooth, which is typical of this condition. Alopecia areata affects approximately 2% of the population at some point in their lives and commonly presents in young adults, consistent with this 23-year-old patient. The condition is thought to be mediated by T-cell attack on hair follicles, causing them to enter a resting phase prematurely.<br /><br /><b>Telogen effluvium</b> is incorrect. This condition presents with diffuse hair thinning rather than discrete patches of hair loss. It typically occurs 2-3 months after a triggering event such as severe illness, major surgery, significant psychological stress, or childbirth. The hair loss in telogen effluvium is generalised across the scalp, with patients often noticing increased hair shedding during washing or brushing. The discrete, well-circumscribed nature of the hair loss in the image is inconsistent with telogen effluvium.<br /><br /><b>Tinea capitis</b> is incorrect. This fungal infection of the scalp, caused by dermatophytes (typically *Trichophyton* or *Microsporum* species), presents with scaly, erythematous patches with broken hair shafts. The affected areas often show inflammation, scaling, and sometimes pustules. The classic 'black dot' appearance occurs when hairs break off at the surface of the scalp. The image shows no evidence of scaling, erythema, or broken hairs, making tinea capitis unlikely.<br /><br /><b>Male-pattern baldness</b> (androgenetic alopecia) is incorrect. This condition presents with a characteristic pattern of progressive hair thinning, typically beginning with recession at the temples and/or thinning at the crown. The hair loss is gradual and symmetrical, following a predictable pattern. The discrete, circular patch of complete hair loss seen in the image is not consistent with the pattern of hair loss seen in male-pattern baldness, which would present with more diffuse thinning rather than complete hair loss in a circumscribed area.<br /><br /><b>Discoid lupus erythematosus</b> is incorrect. This chronic inflammatory condition presents with erythematous, scaly plaques that often lead to scarring alopecia. The affected areas typically show redness, scaling, follicular plugging, and atrophy, with eventual scarring and permanent hair loss. The skin in the image appears normal without evidence of inflammation, scaling, or scarring, making discoid lupus erythematosus an unlikely diagnosis.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 23-year-old man presents as he is concerned about recent hair loss. Examination reveals the following:<br /><br /><CENTER><table><tr><td align = 'left' colspan='2'><img class='ajaximage' src = 'https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/img001.jpg' /></td></tr><tr><td valign='top' align='left'></td><td align='right'></td></tr></table></CENTER><br />What is the most likely diagnosis?",
        "correct_answer": "2",
        "question_notes": "The correct answer is <b>Alopecia areata</b>. This is an autoimmune condition characterised by well-demarcated, smooth, round or oval patches of hair loss without any visible inflammation, scaling, or scarring of the underlying skin. The image shows a classic presentation of alopecia areata with a discrete, circular area of complete hair loss on the scalp. The skin within the affected area appears normal and smooth, which is typical of this condition. Alopecia areata affects approximately 2% of the population at some point in their lives and commonly presents in young adults, consistent with this 23-year-old patient. The condition is thought to be mediated by T-cell attack on hair follicles, causing them to enter a resting phase prematurely.<br /><br /><b>Telogen effluvium</b> is incorrect. This condition presents with diffuse hair thinning rather than discrete patches of hair loss. It typically occurs 2-3 months after a triggering event such as severe illness, major surgery, significant psychological stress, or childbirth. The hair loss in telogen effluvium is generalised across the scalp, with patients often noticing increased hair shedding during washing or brushing. The discrete, well-circumscribed nature of the hair loss in the image is inconsistent with telogen effluvium.<br /><br /><b>Tinea capitis</b> is incorrect. This fungal infection of the scalp, caused by dermatophytes (typically *Trichophyton* or *Microsporum* species), presents with scaly, erythematous patches with broken hair shafts. The affected areas often show inflammation, scaling, and sometimes pustules. The classic 'black dot' appearance occurs when hairs break off at the surface of the scalp. The image shows no evidence of scaling, erythema, or broken hairs, making tinea capitis unlikely.<br /><br /><b>Male-pattern baldness</b> (androgenetic alopecia) is incorrect. This condition presents with a characteristic pattern of progressive hair thinning, typically beginning with recession at the temples and/or thinning at the crown. The hair loss is gradual and symmetrical, following a predictable pattern. The discrete, circular patch of complete hair loss seen in the image is not consistent with the pattern of hair loss seen in male-pattern baldness, which would present with more diffuse thinning rather than complete hair loss in a circumscribed area.<br /><br /><b>Discoid lupus erythematosus</b> is incorrect. This chronic inflammatory condition presents with erythematous, scaly plaques that often lead to scarring alopecia. The affected areas typically show redness, scaling, follicular plugging, and atrophy, with eventual scarring and permanent hair loss. The skin in the image appears normal without evidence of inflammation, scaling, or scarring, making discoid lupus erythematosus an unlikely diagnosis.",
        "answer_order": "2",
        "answer": "2",
        "title": "Alopecia areata",
        "body": "Alopecia areata is a presumed autoimmune condition causing localised, well demarcated patches of hair loss. At the edge of the hair loss, there may be small, broken 'exclamation mark' hairs<br /><br />Hair will regrow in 50% of patients by 1 year, and in 80-90% eventually. Careful explanation is therefore sufficient in many patients. Other treatment options include:<br /><ul><li>topical or intralesional corticosteroids</li><li>topical minoxidil</li><li>phototherapy</li><li>dithranol</li><li>contact immunotherapy</li><li>wigs</li></ul>",
        "notes_hash": "72a3d7bd34ea42f88b14960b49c7e609",
        "knowledge_graph_node_id_link": 1438,
        "concept": "",
        "concept_percentile": 0,
        "concept_colour": "",
        "number_attempts": "5366",
        "up_votes": "24",
        "down_votes": "22",
        "column_array": [
            0,
            "211",
            "4305",
            "743",
            "29",
            "78",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "<table style='width:100%'><tr><td>British Assocaition of Dermatologists</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_953\" data-linkid=\"953\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_953\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">7</span><button type=\"button\" style=\"\" id=\"link_dislike_953\" data-linkid=\"953\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_953\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">10</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"http://www.bad.org.uk/library-media%5Cdocuments%5CAlopecia_areata_guidelines_2012.pdf\">Alopecia areata guidelines</a></td></tr></table>",
        "media": "",
        "comment_count": 7,
        "concepts_for_notes": [],
        "optimisation_reason": ""
    },
    {
        "question_id": "1_B_9477",
        "new_question_id": "11183",
        "question_type": "0",
        "category": "2",
        "concept_id_link": "0",
        "notes_id_link": "1_973",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Topical clindamycin",
            "Topical azelaic acid",
            "Topical benzoyl peroxide",
            "Topical erythromycin",
            "Topical adapalene",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 20-year-old woman who is in the second trimester of her first pregnancy comes for review. Unfortunately her longstanding acne has flared again and she is keen to try something to improve the situation. Which one of the following should be avoided?",
            "",
            ""
        ],
        "answers": [
            "5",
            "",
            ""
        ],
        "notes": [
            "Topical adapalene is a type of retinoid and is therefore strongly contraindicated in pregnancy.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 20-year-old woman who is in the second trimester of her first pregnancy comes for review. Unfortunately her longstanding acne has flared again and she is keen to try something to improve the situation. Which one of the following should be avoided?",
        "correct_answer": "5",
        "question_notes": "Topical adapalene is a type of retinoid and is therefore strongly contraindicated in pregnancy.",
        "answer_order": "5",
        "answer": "5",
        "title": "Acne vulgaris: management",
        "body": "Acne vulgaris is a common skin disorder which usually occurs in adolescence. It typically affects the face, neck and upper trunk and is characterised by the obstruction of the pilosebaceous follicles with keratin plugs which results in comedones, inflammation and pustules.<br /><br />Acne may be classified into mild, moderate or severe:<br /><ul><li>mild: open and closed comedones with or without sparse inflammatory lesions</li><li>moderate acne: widespread non-inflammatory lesions and numerous papules and pustules</li><li>severe acne: extensive inflammatory lesions, which may include nodules, pitting, and scarring</li></ul><br />For people with mild to moderate acne: #link42 <br /><ul><li>a 12-week course of <span class=\"concept\" data-cid=\"2616\">topical combination therapy should be tried first-line</span>:<ul><li>a fixed combination of topical adapalene with topical benzoyl peroxide</li><li>a fixed combination of topical tretinoin with topical clindamycin</li><li>a fixed combination of topical benzoyl peroxide with topical clindamycin</li></ul></li><li>topical benzoyl peroxide may be used as monotherapy if these options are contraindicated or the person wishes to avoid using a topical retinoid or an antibiotic</li></ul><br />For people with <span class=\"concept\" data-cid=\"1117\">moderate to severe acne</span>: #link41 <br /><ul><li>a 12-week course of one of the following options:<ul><li>a fixed combination of topical adapalene with topical benzoyl peroxide </li><li>a fixed combination of topical tretinoin with topical clindamycin </li><li>a fixed combination of topical adapalene with topical benzoyl peroxide + either oral lymecycline or oral doxycycline</li><li>a topical azelaic acid + either oral lymecycline or oral doxycycline</li></ul></li><li>important points about oral antibiotic usage:<ul><li><span class=\"concept\" data-cid=\"1119\">tetracyclines should be avoided in pregnant or breastfeeding women and in children younger than 12 years of age</span>. <span class=\"concept\" data-cid=\"957\">Erythromycin may be used in pregnancy</span></li><li>minocycline is now considered less appropriate due to the possibility of irreversible pigmentation</li><li><span class=\"concept\" data-cid=\"9811\">only continue a treatment option that includes an antibiotic (topical or oral) for more than 6 months in exceptional circumstances</span></li><li>a topical retinoid (if not contraindicated) or benzoyl peroxide should always be co-prescribed with oral antibiotics to reduce the risk of antibiotic resistance developing. <span class=\"concept\" data-cid=\"10230\">Topical and oral antibiotics should not be used in combination</span></li><li>Gram-negative folliculitis may occur as a complication of long-term antibiotic use - high-dose oral trimethoprim is effective if this occurs</li></ul></li><li><span class=\"concept\" data-cid=\"2620\">combined oral contraceptives (COCP) are an alternative to oral antibiotics in women</span><ul><li>as with antibiotics, they should be used in combination with topical agents</li><li><span class=\"concept\" data-cid=\"2621\">Dianette (co-cyprindiol) is sometimes used as it has anti-androgen properties. However, it has an increased risk of venous thromboembolism compared to other COCPs, therefore it should generally be used second-line, only be given for 3 months and women should be appropriately counselled about the risks</span></li></ul></li><li>oral isotretinoin: <span class=\"concept\" data-cid=\"2622\">only under specialist supervision</span><ul><li><span class=\"concept\" data-cid=\"10229\">pregnancy is a contraindication to topical and oral retinoid treatment</span></li></ul></li></ul><br />To reduce the risk of antibiotic resistance developing the following should not be used to treat acne:  #link40 <br /><ul><li><span class=\"concept\" data-cid=\"12096\">monotherapy with a topical antibiotic</span></li><li><span class=\"concept\" data-cid=\"12096\">monotherapy with an oral antibiotic</span></li><li><span class=\"concept\" data-cid=\"10230\">a combination of a topical antibiotic and an oral antibiotic</span></li></ul><br />NICE referral criteria #link39 <br /><ul><li>the following patients should be referred to a dermatologist:<ul><li>patients with acne conglobate acne: a rare and severe form of acne found mostly in men that presents with extensive inflammatory papules, suppurative nodules (that may coalesce to form sinuses) and cysts on the trunk.</li><li>patients with nodulo-cystic acne</li></ul></li><li>referral should be <i>considered</i> in the following scenarios:<ul><li>mild to moderate acne has not responded to two completed courses of treatment</li><li>moderate to severe acne has not responded to previous treatment that includes an oral antibiotic</li><li>acne with <span class=\"concept\" data-cid=\"2618\">scarring</span></li><li>acne with <span class=\"concept\" data-cid=\"2618\">persistent pigmentary changes</span></li><li>acne is causing or contributing to persistent psychological distress or a mental health disorder</li></ul></li></ul>",
        "notes_hash": "7acbc55754b6e1e599a72a38c82e8f56",
        "knowledge_graph_node_id_link": 1352,
        "concept": "",
        "concept_percentile": 0,
        "concept_colour": "",
        "number_attempts": "6162",
        "up_votes": "43",
        "down_votes": "27",
        "column_array": [
            0,
            "935",
            "429",
            "1095",
            "1254",
            "2449",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/zxWh-7IC7HY\" data-description=\"Pharmacology - ACNE TREATMENTS\" data-upvotes=\"21\" data-downvotes=\"4\" data-media=\"1067\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/zxWh-7IC7HY/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/zxWh-7IC7HY\" data-description=\"Pharmacology - ACNE TREATMENTS\" data-upvotes=\"21\" data-downvotes=\"4\" data-media=\"1067\">Pharmacology - ACNE TREATMENTS</a></td></tr><tr><td><span ><small>Speed Pharmacology - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1861\" data-mediaid=\"1861\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_1861\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">21</span><button type=\"button\" style=\"\" id=\"media_dislike_1861\" data-mediaid=\"1861\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_1861\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">4</span></td></tr></table>",
        "comment_count": 3,
        "concepts_for_notes": {
            "957": {
                "concept_text": "Acne vulgaris in pregnancy - use oral erythromycin if treatment needed",
                "concept_percentile": "91"
            },
            "1117": {
                "concept_text": "For moderate-severe acne, one of the following should be used:\n   - topical adapalene with topical benzoyl peroxide \n   - topical tretinoin with topical clindamycin \n   - topical adapalene with topical benzoyl peroxide + either oral lymecycline or oral doxycycline\n   - topical azelaic acid + either oral lymecycline or oral doxycycline",
                "concept_percentile": "35"
            },
            "2622": {
                "concept_text": "Oral isotretinoin must only be used under specialist supervision",
                "concept_percentile": "54"
            }
        },
        "optimisation_reason": ""
    },
    {
        "question_id": "1_B_779",
        "new_question_id": "8986",
        "question_type": "0",
        "category": "2",
        "concept_id_link": "0",
        "notes_id_link": "1_516",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Scleritis",
            "Episcleritis",
            "Keratoconjunctivitis sicca",
            "Corneal ulceration",
            "Keratitis",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "Which one of the following is the most common ocular manifestation of rheumatoid arthritis?",
            "",
            ""
        ],
        "answers": [
            "3",
            "",
            ""
        ],
        "notes": [
            "The correct answer is <b>Keratoconjunctivitis sicca</b>, also known as dry eye syndrome, which affects approximately 15-25% of rheumatoid arthritis (RA) patients. This condition occurs due to autoimmune-mediated inflammation of the lacrimal glands, leading to reduced tear production and subsequent ocular surface damage. It is part of the broader secondary Sj\u00f6gren's syndrome that frequently accompanies RA. Patients typically present with symptoms including foreign body sensation, burning, and ocular fatigue.<br /><br /><b>Scleritis</b> is a serious but less common manifestation of RA, affecting only about 1-6% of patients. It presents with severe ocular pain and redness, and while it can be vision-threatening, it is not the most frequently encountered ocular complication in RA patients.<br /><br /><b>Episcleritis</b> occurs in approximately 5% of RA patients. While more common than scleritis, it is still less frequent than keratoconjunctivitis sicca. It typically presents as acute onset eye redness without significant pain and is generally self-limiting.<br /><br /><b>Corneal ulceration</b> is a relatively rare complication of RA. It usually occurs as a secondary complication of severe keratoconjunctivitis sicca or scleritis, rather than as a primary manifestation. It affects less than 1% of RA patients.<br /><br /><b>Keratitis</b>, while it can occur in RA patients, is not the most common ocular manifestation. It typically develops as a consequence of severe dry eye disease or other primary ocular complications of RA. When it does occur, it's usually in the form of peripheral ulcerative keratitis, but this affects only a small percentage of RA patients.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "Which one of the following is the most common ocular manifestation of rheumatoid arthritis?",
        "correct_answer": "3",
        "question_notes": "The correct answer is <b>Keratoconjunctivitis sicca</b>, also known as dry eye syndrome, which affects approximately 15-25% of rheumatoid arthritis (RA) patients. This condition occurs due to autoimmune-mediated inflammation of the lacrimal glands, leading to reduced tear production and subsequent ocular surface damage. It is part of the broader secondary Sj\u00f6gren's syndrome that frequently accompanies RA. Patients typically present with symptoms including foreign body sensation, burning, and ocular fatigue.<br /><br /><b>Scleritis</b> is a serious but less common manifestation of RA, affecting only about 1-6% of patients. It presents with severe ocular pain and redness, and while it can be vision-threatening, it is not the most frequently encountered ocular complication in RA patients.<br /><br /><b>Episcleritis</b> occurs in approximately 5% of RA patients. While more common than scleritis, it is still less frequent than keratoconjunctivitis sicca. It typically presents as acute onset eye redness without significant pain and is generally self-limiting.<br /><br /><b>Corneal ulceration</b> is a relatively rare complication of RA. It usually occurs as a secondary complication of severe keratoconjunctivitis sicca or scleritis, rather than as a primary manifestation. It affects less than 1% of RA patients.<br /><br /><b>Keratitis</b>, while it can occur in RA patients, is not the most common ocular manifestation. It typically develops as a consequence of severe dry eye disease or other primary ocular complications of RA. When it does occur, it's usually in the form of peripheral ulcerative keratitis, but this affects only a small percentage of RA patients.",
        "answer_order": "3",
        "answer": "3",
        "title": "Rheumatoid arthritis: ocular manifestations",
        "body": "Ocular manifestations of rheumatoid arthritis are common, with 25% of patients having eye problems<br /><br />Ocular manifestations<br /><ul><li>keratoconjunctivitis sicca (most common)</li><li>episcleritis (erythema)</li><li>scleritis (erythema and pain)</li><li>corneal ulceration</li><li>keratitis</li></ul><br />Iatrogenic<br /><ul><li>steroid-induced cataracts</li><li>chloroquine retinopathy</li></ul>",
        "notes_hash": "68a7e662a1be77e9146d440ac6875d74",
        "knowledge_graph_node_id_link": 1093,
        "concept": "",
        "concept_percentile": 0,
        "concept_colour": "",
        "number_attempts": "4329",
        "up_votes": "76",
        "down_votes": "108",
        "column_array": [
            0,
            "1618",
            "1246",
            "1110",
            "55",
            "300",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/rhwe0fb2Um4\" data-description=\"Rheumatoid arthritis\" data-upvotes=\"0\" data-downvotes=\"1\" data-media=\"456\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/rhwe0fb2Um4/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/rhwe0fb2Um4\" data-description=\"Rheumatoid arthritis\" data-upvotes=\"0\" data-downvotes=\"1\" data-media=\"456\">Rheumatoid arthritis</a></td></tr><tr><td><span ><small>Osmosis - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_796\" data-mediaid=\"796\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_796\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">0</span><button type=\"button\" style=\"\" id=\"media_dislike_796\" data-mediaid=\"796\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_796\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1</span></td></tr></table>",
        "comment_count": 8,
        "concepts_for_notes": [],
        "optimisation_reason": ""
    },
    {
        "question_id": "21233_B_62",
        "new_question_id": "43985",
        "question_type": "0",
        "category": "1",
        "concept_id_link": "0",
        "notes_id_link": "1_2021",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "IV adenosine",
            "IV labetalol",
            "No treatment necessary",
            "Transcutaneous pacing",
            "Urgent primary percutaneous coronary intervention",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 92-year-old man is monitored in a cardiac inpatient unit 3 days after an inferior myocardial infarction. He develops new symptoms of light-headedness and has a syncopal event shortly after rising from sitting. <br /><br />His blood pressure is found to be 92/51mmHg whilst lying flat. An ECG is also taken and appears as below:<br /><br /><CENTER><table><tr><td align = 'left' colspan='2'><a data-fancybox class='fancybox' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg100b.png'><img class='ajaximage' src='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg100.png'/></a></td></tr><tr><td valign='top' align='left'> <span style = 'font-size:11px; color:LightGray;'>&copy; Image used on license from </span><a href='http://hqmeded-ecg.blogspot.com/'  target='_blank' style = 'font-size:11px; color:LightGray;' >Dr Smith, University of Minnesota</a></td><td align='right'><a data-fancybox class='fancybox lbmagglasslink' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg100b.png'><img src='https://d32xxyeh8kfs8k.cloudfront.net/css/images/mag_glass.png'/></a><a  border='0' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg100c.png'  \n\t\ttarget='_blank' ><img src='https://d32xxyeh8kfs8k.cloudfront.net/css/images/mag_glass2.png'/></a></td></tr></table></CENTER><br />What intervention might be considered for this patient?",
            "",
            ""
        ],
        "answers": [
            "4",
            "0",
            "0"
        ],
        "notes": [
            "This ECG is showing type 1 second-degree atrioventricular block (Wenckebach). This is seen as a progression in the length of the PR interval until a QRS complex is dropped, regularly. The progressive elongation of the PR interval is particularly visible in the V3-6 leads, although all other leads display it to lesser degrees.<br /><br />In this patient, the inferior MI (i.e. blockage of the right coronary artery which supplies the atrioventricular node) has caused damage to the AVN and created problems with conduction from the atria to the ventricles. This rhythm is often non-pathological (occurring naturally in patients with high vagal tone) and ordinarily asymptomatic and does not require treatment. Even in cases where it is caused by an MI, it normally doesn't require treatment.<br /><br />However, in cases such as this where the patient is symptomatic (typically pre-syncope/syncope, hypotension, bradycardia) and particularly in elderly patients, treatment might be considered, which would primarily consist of <b>transcutaneous pacing</b>. Atropine may also be considered if the patient is bradycardic (not evident here). If normal sinus rhythm doesn't return with these measures, the patient will need pacemaker insertion for definitive management,<br /><br /><b>No treatment necessary</b> is incorrect; this is the normal reaction to Wenckebach but in symptomatic patients, it should be addressed.<br /><br /><b>Urgent primary percutaneous coronary intervention</b> is incorrect; this may be considered if the patient had another MI evident on the ECG.<br /><br /><b>IV labetalol</b> is incorrect. This is used in managing hypertension, particularly in situations like aortic dissection (which likely will have a normal ECG).<br /><br /><b>IV adenosine</b> is incorrect. This is used to manage supraventricular tachycardias, which are shown on ECGs as narrow-complex tachycardias.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 92-year-old man is monitored in a cardiac inpatient unit 3 days after an inferior myocardial infarction. He develops new symptoms of light-headedness and has a syncopal event shortly after rising from sitting. <br /><br />His blood pressure is found to be 92/51mmHg whilst lying flat. An ECG is also taken and appears as below:<br /><br /><CENTER><table><tr><td align = 'left' colspan='2'><a data-fancybox class='fancybox' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg100b.png'><img class='ajaximage' src='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg100.png'/></a></td></tr><tr><td valign='top' align='left'> <span style = 'font-size:11px; color:LightGray;'>&copy; Image used on license from </span><a href='http://hqmeded-ecg.blogspot.com/'  target='_blank' style = 'font-size:11px; color:LightGray;' >Dr Smith, University of Minnesota</a></td><td align='right'><a data-fancybox class='fancybox lbmagglasslink' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg100b.png'><img src='https://d32xxyeh8kfs8k.cloudfront.net/css/images/mag_glass.png'/></a><a  border='0' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg100c.png'  \n\t\ttarget='_blank' ><img src='https://d32xxyeh8kfs8k.cloudfront.net/css/images/mag_glass2.png'/></a></td></tr></table></CENTER><br />What intervention might be considered for this patient?",
        "correct_answer": "4",
        "question_notes": "This ECG is showing type 1 second-degree atrioventricular block (Wenckebach). This is seen as a progression in the length of the PR interval until a QRS complex is dropped, regularly. The progressive elongation of the PR interval is particularly visible in the V3-6 leads, although all other leads display it to lesser degrees.<br /><br />In this patient, the inferior MI (i.e. blockage of the right coronary artery which supplies the atrioventricular node) has caused damage to the AVN and created problems with conduction from the atria to the ventricles. This rhythm is often non-pathological (occurring naturally in patients with high vagal tone) and ordinarily asymptomatic and does not require treatment. Even in cases where it is caused by an MI, it normally doesn't require treatment.<br /><br />However, in cases such as this where the patient is symptomatic (typically pre-syncope/syncope, hypotension, bradycardia) and particularly in elderly patients, treatment might be considered, which would primarily consist of <b>transcutaneous pacing</b>. Atropine may also be considered if the patient is bradycardic (not evident here). If normal sinus rhythm doesn't return with these measures, the patient will need pacemaker insertion for definitive management,<br /><br /><b>No treatment necessary</b> is incorrect; this is the normal reaction to Wenckebach but in symptomatic patients, it should be addressed.<br /><br /><b>Urgent primary percutaneous coronary intervention</b> is incorrect; this may be considered if the patient had another MI evident on the ECG.<br /><br /><b>IV labetalol</b> is incorrect. This is used in managing hypertension, particularly in situations like aortic dissection (which likely will have a normal ECG).<br /><br /><b>IV adenosine</b> is incorrect. This is used to manage supraventricular tachycardias, which are shown on ECGs as narrow-complex tachycardias.",
        "answer_order": "4",
        "answer": "4",
        "title": "Atrioventricular block",
        "body": "In atrioventricular (AV) block, or heart block, there is impaired electrical conduction between the atria and ventricles. There are three types:<br /><br />First-degree heart block<br /><ul><li><span class=\"concept\" data-cid=\"8174\">PR interval > 0.2 seconds</span></li><li>asymptomatic first-degree heart block is relatively common and <span class=\"concept\" data-cid=\"3332\">does not need treatment</span> </li></ul><br /><div class=\"container\"><div class=\"row\"><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg093b.jpg\" data-fancybox=\"gallery\" data-caption=\"ECG showing first-degree heart block - extremely prolonged PR interval of approximately 500 ms - e Image used on license from Dr Smith, University of Minnesota\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg093.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg111b.png\" data-fancybox=\"gallery\" data-caption=\"First degree heart block (250ms), otherwise sinus rhythm, normal ECG\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg111.png\" alt=\"\" /></a></div></div></div><br />Second-degree heart block<br /><ul><li>type 1 (Mobitz I, Wenckebach): <span class=\"concept\" data-cid=\"8176\">progressive prolongation of the PR interval until a dropped beat occurs</span></li><li>type 2 (Mobitz II): <span class=\"concept\" data-cid=\"8177\">PR interval is constant but the P wave is often not followed by a QRS complex</span></li></ul><br /><div class=\"container\"><div class=\"row\"><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd535b.png\" data-fancybox=\"gallery\" data-caption=\"Mobitz I, Wenckebach\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd535.png\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg100b.png\" data-fancybox=\"gallery\" data-caption=\"ECG showing type 1 secondary degree heart block (Wenckebach) - e Image used on license from Dr Smith, University of Minnesota\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ecg100.png\" alt=\"\" /></a></div></div></div><br />Third-degree (complete) heart block<br /><ul><li><span class=\"concept\" data-cid=\"8175\">there is no association between the P waves and QRS complexes</span></li></ul><br /><div class=\"container\"><div class=\"row\"><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd534b.png\" data-fancybox=\"gallery\" data-caption=\"Complete AV block and resulting junctional escape\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd534.png\" alt=\"\" /></a></div></div></div><br /><CENTER><table><tr><td align = 'left' colspan='2'><a data-fancybox class='fancybox' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd533b.png'><img class='ajaximage' src='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd533.png'/></a></td></tr><tr><td valign='top' align='left'></td><td align='right'><a data-fancybox class='fancybox lbmagglasslink' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd533b.png'><img src='https://d32xxyeh8kfs8k.cloudfront.net/css/images/mag_glass.png'/></a></td></tr></table></CENTER><div class='imagetext'>ECG showing types of heart block</div>",
        "notes_hash": "9b8de23b49d2de3091353b056965484a",
        "knowledge_graph_node_id_link": 0,
        "concept": "",
        "concept_percentile": 0,
        "concept_colour": "",
        "number_attempts": "2894",
        "up_votes": "3",
        "down_votes": "3",
        "column_array": [
            0,
            "164",
            "111",
            "248",
            "2109",
            "262",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/lGTjE6jE3P4\" data-description=\"Heart Blocks Made Easy - 1st, 2nd (Mobitz 1/Wenckebach & Mobitz 2), 3rd (Complete)\" data-upvotes=\"14\" data-downvotes=\"0\" data-media=\"1389\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/lGTjE6jE3P4/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/lGTjE6jE3P4\" data-description=\"Heart Blocks Made Easy - 1st, 2nd (Mobitz 1/Wenckebach & Mobitz 2), 3rd (Complete)\" data-upvotes=\"14\" data-downvotes=\"0\" data-media=\"1389\">Heart Blocks Made Easy - 1st, 2nd (Mobitz 1/Wenckebach & Mobitz 2), 3rd (Complete)</a></td></tr><tr><td><span ><small>Rhesus Medicine - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2443\" data-mediaid=\"2443\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_2443\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">14</span><button type=\"button\" style=\"\" id=\"media_dislike_2443\" data-mediaid=\"2443\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_2443\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">0</span></td></tr><tr><td>&nbsp;</td></tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://upload.wikimedia.org/wikipedia/commons/5/59/AV_Block_video.webm\" data-description=\"Atrioventricular block\" data-upvotes=\"6\" data-downvotes=\"1\" data-media=\"980\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/css/images/osmosis.png\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://upload.wikimedia.org/wikipedia/commons/5/59/AV_Block_video.webm\" data-description=\"Atrioventricular block\" data-upvotes=\"6\" data-downvotes=\"1\" data-media=\"980\">Atrioventricular block</a></td></tr><tr><td><span ><small>Osmosis - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1704\" data-mediaid=\"1704\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_1704\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">6</span><button type=\"button\" style=\"\" id=\"media_dislike_1704\" data-mediaid=\"1704\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_1704\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1</span></td></tr><tr><td>&nbsp;</td></tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/iiinZvwBSuE\" data-description=\"AV block\" data-upvotes=\"1\" data-downvotes=\"1\" data-media=\"373\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/iiinZvwBSuE/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/iiinZvwBSuE\" data-description=\"AV block\" data-upvotes=\"1\" data-downvotes=\"1\" data-media=\"373\">AV block</a></td></tr><tr><td><span ><small>Strong Medicine - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_632\" data-mediaid=\"632\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_632\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">1</span><button type=\"button\" style=\"\" id=\"media_dislike_632\" data-mediaid=\"632\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_632\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1</span></td></tr></table>",
        "comment_count": 0,
        "concepts_for_notes": {
            "8174": {
                "concept_text": "A 50-year-old cycling enthusiast is found to have a PR interval of 0.24 seconds on a routine ECG. The ECG is otherwise normal - first degree heart block",
                "concept_percentile": "42"
            },
            "8175": {
                "concept_text": "A patient develops a bradycardia of 36/min following a myocardial infarction. The ECG shows no association between the P waves and QRS complexes - complete heart block",
                "concept_percentile": "23"
            },
            "8176": {
                "concept_text": "Progressive prolongation of the PR interval until a dropped beat occurs - second degree heart block (Mobitz type I)",
                "concept_percentile": "48"
            },
            "8177": {
                "concept_text": "PR interval is constant but the P wave is often not followed by a QRS complex - second degree heart block (Mobitz type II)",
                "concept_percentile": "50"
            }
        },
        "optimisation_reason": ""
    },
    {
        "question_id": "999_B_2162",
        "new_question_id": "61243",
        "question_type": "0",
        "category": "8",
        "concept_id_link": "1487",
        "notes_id_link": "1_1214",
        "theme": "Tumour marker for colorectal cancer surveillance",
        "instruction": "",
        "options": [
            "",
            "CA 19-9",
            "CA 125",
            "Alpha-fetoprotein",
            "Carcinoembryonic antigen",
            "Prostate-specific antigen",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 65-year-old man, two years post-right hemicolectomy for colorectal cancer, attends a routine follow-up clinic. He is asymptomatic with a normal examination.<br /><br />Select the single most appropriate blood test to monitor for disease recurrence.",
            "",
            ""
        ],
        "answers": [
            "4",
            "",
            ""
        ],
        "notes": [
            "<b>Carcinoembryonic antigen (CEA)</b> is the correct answer. CEA is a glycoprotein that is overexpressed in many adenocarcinomas, most notably colorectal cancer. While it has poor sensitivity and specificity for initial diagnosis (as it can be elevated in various non-malignant conditions like inflammatory bowel disease, pancreatitis, and in smokers), it is the established and recommended tumour marker for the post-operative surveillance of colorectal cancer. According to UK NICE guidelines (NG151), regular CEA testing is a core component of follow-up for patients who have undergone curative-intent surgery for colorectal cancer. A rising CEA level on serial testing is a significant indicator of disease recurrence, often preceding clinical or radiological evidence of metastases. An elevated or rising CEA should prompt further investigation, typically with a CT scan of the chest, abdomen, and pelvis, to locate the site of recurrence. In this 65-year-old man who is two years post-hemicolectomy, monitoring his CEA level is the standard of care to detect potential recurrence at an early, and potentially treatable, stage.<br /><br /><b>CA 19-9</b> is an incorrect option. While CA 19-9 is a tumour marker associated with gastrointestinal malignancies, its primary clinical utility is in the management of pancreatic cancer. It can be used to monitor treatment response and detect recurrence in patients with pancreatic adenocarcinoma. Although elevations in CA 19-9 can be seen in other cancers, including colorectal, gastric, and biliary tract cancers, it is not the primary or recommended marker for colorectal cancer surveillance. CEA has been shown to be more sensitive and specific for colorectal cancer recurrence. Using CA 19-9 in this context would be non-standard and could be misleading. The NICE guidelines for colorectal cancer follow-up specifically recommend CEA, not CA 19-9. Therefore, for this patient with a history of colorectal cancer, CEA is the most appropriate blood test for monitoring.<br /><br /><b>CA 125</b> is incorrect. This tumour marker is most famously associated with epithelial ovarian cancer. It is the cornerstone of monitoring for recurrence in women treated for ovarian cancer and can be used in conjunction with imaging to assess treatment response. It has no established role in the surveillance of colorectal cancer, particularly in a male patient. While it can be non-specifically elevated in other conditions, including other malignancies and benign conditions like endometriosis or pelvic inflammatory disease, it is not a useful marker for colorectal cancer. Selecting this option would demonstrate a fundamental misunderstanding of the clinical application of common tumour markers.<br /><br /><b>Alpha-fetoprotein (AFP)</b> is not the correct choice. AFP is a crucial tumour marker for two main types of cancer: hepatocellular carcinoma (HCC) and non-seminomatous germ cell tumours (e.g., yolk sac tumours). While it is true that the liver is the most common site for metastatic spread from colorectal cancer, the metastases themselves do not typically produce AFP. Monitoring for liver metastases in this patient would involve regular liver function tests and imaging (such as CT or ultrasound), guided by symptoms or a rising CEA level. AFP levels would not be expected to rise with the development of colorectal liver metastases. Therefore, measuring AFP has no role in the routine follow-up of a patient post-resection for colorectal cancer.<br /><br /><b>Prostate-specific antigen (PSA)</b> is an incorrect choice. PSA is an enzyme produced by the epithelial cells of the prostate gland. It is a highly specific marker for prostate tissue and is used extensively in the screening, diagnosis, and monitoring of prostate cancer. A 65-year-old man is in the at-risk age group for prostate cancer, making this a plausible distractor. However, the clinical question is specifically about monitoring for the recurrence of his known colorectal cancer. PSA has no association with colorectal cancer and measuring it would not provide any information about the status of his previous disease. While a GP might consider checking a PSA as part of a general health check for a man of this age, it is not the appropriate investigation for colorectal cancer surveillance.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 65-year-old man, two years post-right hemicolectomy for colorectal cancer, attends a routine follow-up clinic. He is asymptomatic with a normal examination.<br /><br />Select the single most appropriate blood test to monitor for disease recurrence.",
        "correct_answer": "4",
        "question_notes": "<b>Carcinoembryonic antigen (CEA)</b> is the correct answer. CEA is a glycoprotein that is overexpressed in many adenocarcinomas, most notably colorectal cancer. While it has poor sensitivity and specificity for initial diagnosis (as it can be elevated in various non-malignant conditions like inflammatory bowel disease, pancreatitis, and in smokers), it is the established and recommended tumour marker for the post-operative surveillance of colorectal cancer. According to UK NICE guidelines (NG151), regular CEA testing is a core component of follow-up for patients who have undergone curative-intent surgery for colorectal cancer. A rising CEA level on serial testing is a significant indicator of disease recurrence, often preceding clinical or radiological evidence of metastases. An elevated or rising CEA should prompt further investigation, typically with a CT scan of the chest, abdomen, and pelvis, to locate the site of recurrence. In this 65-year-old man who is two years post-hemicolectomy, monitoring his CEA level is the standard of care to detect potential recurrence at an early, and potentially treatable, stage.<br /><br /><b>CA 19-9</b> is an incorrect option. While CA 19-9 is a tumour marker associated with gastrointestinal malignancies, its primary clinical utility is in the management of pancreatic cancer. It can be used to monitor treatment response and detect recurrence in patients with pancreatic adenocarcinoma. Although elevations in CA 19-9 can be seen in other cancers, including colorectal, gastric, and biliary tract cancers, it is not the primary or recommended marker for colorectal cancer surveillance. CEA has been shown to be more sensitive and specific for colorectal cancer recurrence. Using CA 19-9 in this context would be non-standard and could be misleading. The NICE guidelines for colorectal cancer follow-up specifically recommend CEA, not CA 19-9. Therefore, for this patient with a history of colorectal cancer, CEA is the most appropriate blood test for monitoring.<br /><br /><b>CA 125</b> is incorrect. This tumour marker is most famously associated with epithelial ovarian cancer. It is the cornerstone of monitoring for recurrence in women treated for ovarian cancer and can be used in conjunction with imaging to assess treatment response. It has no established role in the surveillance of colorectal cancer, particularly in a male patient. While it can be non-specifically elevated in other conditions, including other malignancies and benign conditions like endometriosis or pelvic inflammatory disease, it is not a useful marker for colorectal cancer. Selecting this option would demonstrate a fundamental misunderstanding of the clinical application of common tumour markers.<br /><br /><b>Alpha-fetoprotein (AFP)</b> is not the correct choice. AFP is a crucial tumour marker for two main types of cancer: hepatocellular carcinoma (HCC) and non-seminomatous germ cell tumours (e.g., yolk sac tumours). While it is true that the liver is the most common site for metastatic spread from colorectal cancer, the metastases themselves do not typically produce AFP. Monitoring for liver metastases in this patient would involve regular liver function tests and imaging (such as CT or ultrasound), guided by symptoms or a rising CEA level. AFP levels would not be expected to rise with the development of colorectal liver metastases. Therefore, measuring AFP has no role in the routine follow-up of a patient post-resection for colorectal cancer.<br /><br /><b>Prostate-specific antigen (PSA)</b> is an incorrect choice. PSA is an enzyme produced by the epithelial cells of the prostate gland. It is a highly specific marker for prostate tissue and is used extensively in the screening, diagnosis, and monitoring of prostate cancer. A 65-year-old man is in the at-risk age group for prostate cancer, making this a plausible distractor. However, the clinical question is specifically about monitoring for the recurrence of his known colorectal cancer. PSA has no association with colorectal cancer and measuring it would not provide any information about the status of his previous disease. While a GP might consider checking a PSA as part of a general health check for a man of this age, it is not the appropriate investigation for colorectal cancer surveillance.",
        "answer_order": "4",
        "answer": "4",
        "title": "Tumour markers",
        "body": "Tumour markers may be divided into:<br /><ul><li>monoclonal antibodies against carbohydrate or glycoprotein tumour antigens</li><li>tumour antigens</li><li>enzymes (alkaline phosphatase, neurone specific enolase)</li><li>hormones (e.g. calcitonin, ADH)</li></ul><br />It should be noted that tumour markers usually have a low specificity<br /><br /><h5 class='notes-heading'>Monoclonal antibodies</h5><br /><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th><b>Tumour marker</b></th><th><b>Association</b></th></tr></thead><tbody><tr><td>CA 125</td><td><span class=\"concept\" data-cid=\"7679\">Ovarian cancer</span></td></tr><tr><td>CA 19-9</td><td><span class=\"concept\" data-cid=\"7680\">Pancreatic cancer</span></td></tr><tr><td>CA 15-3</td><td><span class=\"concept\" data-cid=\"4848\">Breast cancer</span></td></tr></tbody></table></div><br /><h5 class='notes-heading'>Tumour antigens</h5><br /><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid2\" ><thead><tr><th><b>Tumour marker</b></th><th><b>Association</b></th></tr></thead><tbody><tr><td>Prostate specific antigen (PSA)</td><td>Prostatic carcinoma</td></tr><tr><td>Alpha-feto protein (AFP)</td><td><span class=\"concept\" data-cid=\"7681\">Hepatocellular carcinoma</span>, <span class=\"concept\" data-cid=\"7682\">teratoma</span></td></tr><tr><td>Carcinoembryonic antigen (CEA)</td><td><span class=\"concept\" data-cid=\"1487\">Colorectal cancer</span></td></tr><tr><td>S-100</td><td><span class=\"concept\" data-cid=\"7683\">Melanoma</span>, <span class=\"concept\" data-cid=\"7684\">schwannoma</span>s</td></tr><tr><td>Bombesin</td><td><span class=\"concept\" data-cid=\"4847\">Small cell lung carcinoma</span>, gastric cancer, <span class=\"concept\" data-cid=\"7685\">neuroblastoma</span></td></tr></tbody></table></div>",
        "notes_hash": "d890e7160baff9038e40eaa6766d412e",
        "knowledge_graph_node_id_link": 10569,
        "concept": "Carcinoembryonic Antigen (CEA) is a tumour marker in colorectal cancer and has a role in monitoring disease activity",
        "concept_percentile": "38",
        "concept_colour": "rgb(255,193,0)",
        "number_attempts": "163",
        "up_votes": "0",
        "down_votes": "1",
        "column_array": [
            0,
            "3",
            "4",
            "9",
            "147",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "<table style='width:100%'><tr><td>National Cancer Institute</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_96\" data-linkid=\"96\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_96\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">35</span><button type=\"button\" style=\"\" id=\"link_dislike_96\" data-linkid=\"96\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_96\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">19</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet\">Tumour markers</a></td></tr></table>",
        "media": "",
        "comment_count": 0,
        "concepts_for_notes": {
            "1487": {
                "concept_text": "Carcinoembryonic Antigen (CEA) is a tumour marker in colorectal cancer and has a role in monitoring disease activity",
                "concept_percentile": "38"
            },
            "4848": {
                "concept_text": "CA 15-3 is a tumour marker in breast cancers",
                "concept_percentile": "27"
            },
            "7679": {
                "concept_text": "Ovarian cancer - CA 125",
                "concept_percentile": "17"
            },
            "7680": {
                "concept_text": "Pancreatic cancer - CA 19-9",
                "concept_percentile": "33"
            },
            "7681": {
                "concept_text": "Hepatocellular carcinoma - alpha-feto protein",
                "concept_percentile": "50"
            },
            "7682": {
                "concept_text": "Teratoma - alpha-feto protein",
                "concept_percentile": "35"
            }
        },
        "optimisation_reason": ""
    },
    {
        "question_id": "10156_B_47",
        "new_question_id": "20829",
        "question_type": "0",
        "category": "1",
        "concept_id_link": "9850",
        "notes_id_link": "1_915",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Add spironolactone",
            "Add metoprolol",
            "Add candesartan",
            "Cease amlodipine and swap to ramipril",
            "Increase dose of amlodipine",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "Stephanie is a 50-year-old black woman who presents to her general practitioner for routine check-up of her hypertension. At her last two appointments, her hypertension has been poorly controlled, despite current treatment with amlodipine 10mg once daily. On examination today, her blood pressure is 160/100mmHg, pulse 70/minute, respiratory rate 15/min, and she is afebrile. <br /><br />In order to attempt to control Stephanie's hypertension, what would be the next appropriate action?",
            "",
            ""
        ],
        "answers": [
            "3",
            "0",
            "0"
        ],
        "notes": [
            "In patients already taking a calcium channel blocker, the next step to manage their poorly controlled hypertension is to add an ACE inhibitor or angiotensin receptor blocker (ARB) or a thiazide-like diuretic. In this case, as she is black an ARB is the better choice.<br /><br />Metoprolol is a beta-blocker, and this is not used often in the management of hypertension. <br /><br />Increasing the dose of amlodipine would increase the potential risk of side effects, and for this reason it is generally better to add multiple drugs at lower doses, than to increase one drug to a maximum dose.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "Stephanie is a 50-year-old black woman who presents to her general practitioner for routine check-up of her hypertension. At her last two appointments, her hypertension has been poorly controlled, despite current treatment with amlodipine 10mg once daily. On examination today, her blood pressure is 160/100mmHg, pulse 70/minute, respiratory rate 15/min, and she is afebrile. <br /><br />In order to attempt to control Stephanie's hypertension, what would be the next appropriate action?",
        "correct_answer": "3",
        "question_notes": "In patients already taking a calcium channel blocker, the next step to manage their poorly controlled hypertension is to add an ACE inhibitor or angiotensin receptor blocker (ARB) or a thiazide-like diuretic. In this case, as she is black an ARB is the better choice.<br /><br />Metoprolol is a beta-blocker, and this is not used often in the management of hypertension. <br /><br />Increasing the dose of amlodipine would increase the potential risk of side effects, and for this reason it is generally better to add multiple drugs at lower doses, than to increase one drug to a maximum dose.",
        "answer_order": "3",
        "answer": "3",
        "title": "Hypertension: management",
        "body": "NICE published updated guidelines for the management of hypertension in 2019. Some of the key changes include:<br /><ul><li>lowering the threshold for treating stage 1 hypertension in patients < 80 years from 20% to 10%</li><li>angiotensin receptor blockers can be used instead of ACE-inhibitors where indicated</li><li>if a patient is already taking an ACE-inhibitor or angiotensin receptor blocker, then a calcium channel blocker OR a thiazide-like diuretic can be used. Previously only a calcium channel blocker was recommended</li></ul><br /><h5 class='notes-heading'>Blood pressure classification</h5><br />This becomes relevant later in some of the management decisions that NICE advocates.<br /><br /><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th><b>Stage</b></th><th><b>Criteria</b></th></tr></thead><tbody><tr><td><b>Stage 1 hypertension</b></td><td>Clinic BP >= <span class=\"concept\" data-cid=\"6674\">140/90 mmHg</span> and subsequent ABPM daytime average or HBPM average BP >= <span class=\"concept\" data-cid=\"6675\">135/85 mmHg</span></td></tr><tr><td><b>Stage 2 hypertension</b></td><td>Clinic BP >= <span class=\"concept\" data-cid=\"6676\">160/100 mmHg</span> and subsequent ABPM daytime average or HBPM average BP >= <span class=\"concept\" data-cid=\"6677\">150/95 mmHg</span></td></tr><tr><td><b>Severe hypertension</b></td><td><span class=\"concept\" data-cid=\"6673\">Clinic systolic BP >= 180 mmHg, or clinic diastolic BP >= 120 mmHg</span></td></tr></tbody></table></div><br /><CENTER><table><tr><td align = 'left' colspan='2'><a data-fancybox class='fancybox' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd927b.png'><img class='ajaximage' src='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd927.png'/></a></td></tr><tr><td valign='top' align='left'></td><td align='right'><a data-fancybox class='fancybox lbmagglasslink' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd927b.png'><img src='https://d32xxyeh8kfs8k.cloudfront.net/css/images/mag_glass.png'/></a></td></tr></table></CENTER><div class='imagetext'>Flow chart showing simplified schematic for diagnosis hypertension following NICE guidelines</div><br /><h5 class='notes-heading'>Managing hypertension</h5><br />Lifestyle advice should not be forgotten and is frequently tested in exams:<br /><ul><li><span class=\"concept\" data-cid=\"10294\">a low salt diet is recommended, aiming for less than 6g/day</span>, ideally 3g/day. The average adult in the UK consumes around 8-12g/day of salt. A recent BMJ paper* showed that lowering salt intake can have a significant effect on blood pressure. For example, reducing salt intake by 6g/day can lower systolic blood pressure by 10mmHg</li><li>caffeine intake should be reduced</li><li>the other general bits of advice remain: stop smoking, drink less alcohol, eat a balanced diet rich in fruit and vegetables, exercise more, lose weight</li></ul><br />ABPM/HBPM >= <span class=\"concept\" data-cid=\"6675\">135/85 mmHg</span> (i.e. stage 1 hypertension)<br /><ul><li>treat if < 80 years of age AND any of the following apply; target organ damage, established cardiovascular disease, renal disease, diabetes or a 10-year cardiovascular risk equivalent to 10% or greater</li><li>in 2019, NICE made a further recommendation, suggesting that we should <i>'consider antihypertensive drug treatment in addition to lifestyle advice for adults aged under 60 with stage 1 hypertension and an estimated 10-year risk below 10%. '</i>. This seems to be due to evidence that QRISK may underestimate the lifetime probability of developing cardiovascular disease</li></ul><br />ABPM/HBPM >= <span class=\"concept\" data-cid=\"6677\">150/95 mmHg</span> (i.e. stage 2 hypertension)<br /><ul><li>offer drug treatment regardless of age</li></ul><br />For patients < 40 years consider specialist referral to exclude secondary causes.<br /><br /><br /><CENTER><table><tr><td align = 'left' colspan='2'><a data-fancybox class='fancybox' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd566b.png'><img class='ajaximage' src='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd566.png'/></a></td></tr><tr><td valign='top' align='left'></td><td align='right'><a data-fancybox class='fancybox lbmagglasslink' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd566b.png'><img src='https://d32xxyeh8kfs8k.cloudfront.net/css/images/mag_glass.png'/></a></td></tr></table></CENTER><div class='imagetext'>Flow chart showing the management of hypertension as per current NICE guideliness</div><br /><br />Step 1 treatment<br /><ul><li><span class=\"concept\" data-cid=\"6670\">patients < 55-years-old</span> or a background of <span class=\"concept\" data-cid=\"9851\">type 2 diabetes mellitus</span>: <b>A</b>CE inhibitor or a <b>A</b>ngiotensin receptor blocker (<b>A</b>CE-i or <b>A</b>RB): <b>(A)</b><ul><li><span class=\"concept\" data-cid=\"922\">angiotensin receptor blockers should be used where ACE inhibitors are not tolerated (e.g. due to a cough)</span></li></ul></li><li><span class=\"concept\" data-cid=\"6671\">patients >= 55-years-old</span> or of <span class=\"concept\" data-cid=\"6672\">black African or African-Caribbean origin</span>: <b>C</b>alcium channel blocker <b>(C)</b><ul><li><span class=\"concept\" data-cid=\"916\">ACE inhibitors have reduced efficacy in patients of black African or African-Caribbean origin are therefore not used first-line</span></li></ul></li></ul><br />Step 2 treatment<br /><ul><li><span class=\"concept\" data-cid=\"6682\">if already taking an <b>A</b>CE-i or <b>A</b>RB add a <b>C</b>alcium channel blocker or a thiazide-like <b>D</b>iuretic</span></li><li><span class=\"concept\" data-cid=\"9850\">if already taking a <b>C</b>alcium channel blocker add an <b>A</b>CE-i or <b>A</b>RB or a thiazide-like <b>D</b>iuretic</span><ul><li><span class=\"concept\" data-cid=\"1386\">for patients of black African or African-Caribbean origin taking a calcium channel blocker for hypertension, if they require a second agent consider an angiotensin receptor blocker in preference to an ACE inhibitor</span></li></ul></li><li><b>(A + C) or (A + D)</b> or <b>(C + A) or (C + D)</b> </li></ul><br />Step 3 treatment<br /><ul><li>add a third drug to make, i.e.:<ul><li><span class=\"concept\" data-cid=\"6683\">if already taking an <b>(A + C)</b> then add a <b>D</b></span></li><li><span class=\"concept\" data-cid=\"9849\">if already <b>(A + D)</b> then add a <b>C</b></span></li></ul></li><li><b>(A + C + D)</b> </li></ul><br />Step 4 treatment<br /><ul><li>NICE define step 4 as resistant hypertension and suggest either adding a 4<sup>th</sup> drug (as below) or seeking specialist advice</li><li>first, check for:<ul><li>confirm elevated clinic BP with ABPM or HBPM</li><li>assess for postural hypotension.</li><li>discuss adherence</li></ul></li><li><span class=\"concept\" data-cid=\"6684\">if potassium < 4.5 mmol/l add low-dose spironolactone</span></li><li><span class=\"concept\" data-cid=\"6685\">if potassium > 4.5 mmol/l add an alpha- or beta-blocker</span></li></ul><br />Patients who fail to respond to step 4 measures should be referred to a specialist. NICE recommend:<br /><div class='bs-callout bs-callout-default'><i><i><br />If blood pressure remains uncontrolled with the optimal or maximum tolerated doses of four drugs, seek expert advice if it has not yet been obtained. <br /></i></i></div><br /><div class=\"container\"><div class=\"row\"><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd973b.png\" data-fancybox=\"gallery\" data-caption=\"\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd973.png\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd974b.png\" data-fancybox=\"gallery\" data-caption=\"\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd974.png\" alt=\"\" /></a></div></div></div><br /><h5 class='notes-heading'>Blood pressure targets</h5><br /><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid2\" ><thead><tr><th></th><th><b>Clinic BP</b></th><th><b>ABPM / HBPM</b></th></tr></thead><tbody><tr><td><b>Age < 80 years</b></td><td><span class=\"concept\" data-cid=\"6678\">140/90 mmHg</span></td><td><span class=\"concept\" data-cid=\"6680\">135/85 mmHg</span></td></tr><tr><td><b>Age > 80 years</b></td><td><span class=\"concept\" data-cid=\"6679\">150/90 mmHg</span></td><td><span class=\"concept\" data-cid=\"6681\">145/85 mmHg</span></td></tr></tbody></table></div>",
        "notes_hash": "95248e6fb11c2374837320c9bd891a27",
        "knowledge_graph_node_id_link": 10012,
        "concept": "Poorly controlled hypertension, already taking a calcium channel blocker - add an ACE inhibitor or an angiotensin receptor blocker or a thiazide-like diuretic",
        "concept_percentile": "46",
        "concept_colour": "rgb(255,234,0)",
        "number_attempts": "7030",
        "up_votes": "24",
        "down_votes": "8",
        "column_array": [
            0,
            "228",
            "192",
            "6146",
            "200",
            "264",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "<table style='width:100%'><tr><td>NICE</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_978\" data-linkid=\"978\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_978\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">134</span><button type=\"button\" style=\"\" id=\"link_dislike_978\" data-linkid=\"978\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_978\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">121</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.nice.org.uk/guidance/ng136/chapter/Recommendations\">2019 Hypertension guidelines</a></td></tr></table>",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/LnGB7U1xIuw\" data-description=\"Hypertension Explained\" data-upvotes=\"14\" data-downvotes=\"8\" data-media=\"1380\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/LnGB7U1xIuw/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/LnGB7U1xIuw\" data-description=\"Hypertension Explained\" data-upvotes=\"14\" data-downvotes=\"8\" data-media=\"1380\">Hypertension Explained</a></td></tr><tr><td><span ><small>Rhesus Medicine - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2429\" data-mediaid=\"2429\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_2429\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">14</span><button type=\"button\" style=\"\" id=\"media_dislike_2429\" data-mediaid=\"2429\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_2429\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">8</span></td></tr></table>",
        "comment_count": 3,
        "concepts_for_notes": {
            "922": {
                "concept_text": "Angiotensin-receptor blockers should be used where ACE inhibitors are not tolerated",
                "concept_percentile": "32"
            },
            "1386": {
                "concept_text": "For patients of black African or African-Caribbean origin taking a calcium channel blocker for hypertension, if they require a second agent consider an angiotensin receptor blocker in preference to an ACE inhibitor",
                "concept_percentile": "73"
            },
            "6670": {
                "concept_text": "Newly diagnosed patient with hypertension (< 55 years) - add an ACE inhibitor or an angiotensin receptor blocker",
                "concept_percentile": "43"
            },
            "6671": {
                "concept_text": "Newly diagnosed patient with hypertension (> 55 years) - add a calcium channel blocker",
                "concept_percentile": "21"
            },
            "6672": {
                "concept_text": "Newly diagnosed patient of black African or African-Caribbean origin with hypertension - add a calcium channel blocker",
                "concept_percentile": "37"
            },
            "6673": {
                "concept_text": "Criteria for considering immediate treatment based on a clinic reading - 180/120 mmHg",
                "concept_percentile": "16"
            },
            "6674": {
                "concept_text": "Definition of stage 1 hypertension (Clinic reading) - 140/90 mmHg",
                "concept_percentile": "46"
            },
            "6675": {
                "concept_text": "Definition of stage 1 hypertension (ABPM/HBPM) - 135/85 mmHg",
                "concept_percentile": "19"
            },
            "6676": {
                "concept_text": "Definition of stage 2 hypertension (Clinic reading) - 160/100 mmHg",
                "concept_percentile": "34"
            },
            "6677": {
                "concept_text": "Definition of stage 2 hypertension (ABPM/HBPM) - 150/95 mmHg",
                "concept_percentile": "21"
            },
            "6678": {
                "concept_text": "Blood pressure target (< 80 years, clinic reading) - 140/90 mmHg",
                "concept_percentile": "26"
            },
            "6679": {
                "concept_text": "Blood pressure target (> 80 years, clinic reading) - 150/90 mmHg",
                "concept_percentile": "24"
            },
            "6680": {
                "concept_text": "Blood pressure target (< 80 years, ABPM/HBPM) - 135/85 mmHg",
                "concept_percentile": "23"
            },
            "6681": {
                "concept_text": "Blood pressure target (> 80 years, ABPM/HBPM) - 145/85 mmHg",
                "concept_percentile": "26"
            },
            "6682": {
                "concept_text": "Poorly controlled hypertension, already taking an ACE inhibitor - add a calcium channel blocker or a thiazide-like diuretic",
                "concept_percentile": "47"
            },
            "6683": {
                "concept_text": "Poorly controlled hypertension, already taking an ACE inhibitor and a calcium channel blocker - add a thiazide-like diuretic",
                "concept_percentile": "52"
            },
            "6684": {
                "concept_text": "Poorly controlled hypertension, already taking an ACE inhibitor, calcium channel blocker and a thiazide diuretic. K+ < 4.5mmol/l - add spironolactone",
                "concept_percentile": "56"
            },
            "6685": {
                "concept_text": "Poorly controlled hypertension, already taking an ACE inhibitor, calcium channel blocker and a standard-dose thiazide diuretic. K+ > 4.5mmol/l - add an alpha- or beta-blocker",
                "concept_percentile": "60"
            },
            "9849": {
                "concept_text": "Poorly controlled hypertension, already taking an ACE inhibitor and a thiazide diuretic - add a calcium channel blocker",
                "concept_percentile": "24"
            },
            "9850": {
                "concept_text": "Poorly controlled hypertension, already taking a calcium channel blocker - add an ACE inhibitor or an angiotensin receptor blocker or a thiazide-like diuretic",
                "concept_percentile": "46"
            },
            "9851": {
                "concept_text": "Newly diagnosed patient with hypertension who has a background of type 2 diabetes mellitus - add an ACE inhibitor or an angiotensin receptor blocker regardless of age",
                "concept_percentile": "72"
            }
        },
        "optimisation_reason": ""
    },
    {
        "question_id": "5650_B_97",
        "new_question_id": "26207",
        "question_type": "0",
        "category": "6",
        "concept_id_link": "552",
        "notes_id_link": "1_2252",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Advise on healthy diet containing calcium-rich foods",
            "Prescription of alendronate",
            "Prescription of calcium supplements",
            "Prescription of zoledronic acid",
            "Refer for DEXA scan prior to any prescription",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 77-year-old female patient has a home visit from her general practitioner for follow-up after sustaining fractured neck of femur slipping on ice.  She reports to feel well in herself and is progressing with the rehabilitation programme advised to her at discharge and is not reliant on analgesia any longer.  She had no previous medical or surgical history prior to the fall.  The patient would like some advice regarding preventing future fractures.  <br /><br />Which, of the options below, is appropriate?",
            "",
            ""
        ],
        "answers": [
            "2",
            "0",
            "0"
        ],
        "notes": [
            "This patient fulfils the NICE criteria for starting a bisphosphonate without waiting for a DEXA scan as she is \u2265 75 years of age and has sustained a fragility fracture in her neck of femur.  <br /><br />A calcium rich diet and calcium supplementation may further benefit the patient, however this will not adequately manage her likely osteoporosis.<br /><br />Zoledronic acid may be an appropriate alternative if this patient is unable to tolerate bisphosphonates but should not be offered first line.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 77-year-old female patient has a home visit from her general practitioner for follow-up after sustaining fractured neck of femur slipping on ice.  She reports to feel well in herself and is progressing with the rehabilitation programme advised to her at discharge and is not reliant on analgesia any longer.  She had no previous medical or surgical history prior to the fall.  The patient would like some advice regarding preventing future fractures.  <br /><br />Which, of the options below, is appropriate?",
        "correct_answer": "2",
        "question_notes": "This patient fulfils the NICE criteria for starting a bisphosphonate without waiting for a DEXA scan as she is \u2265 75 years of age and has sustained a fragility fracture in her neck of femur.  <br /><br />A calcium rich diet and calcium supplementation may further benefit the patient, however this will not adequately manage her likely osteoporosis.<br /><br />Zoledronic acid may be an appropriate alternative if this patient is unable to tolerate bisphosphonates but should not be offered first line.",
        "answer_order": "2",
        "answer": "2",
        "title": "Osteoporosis: Assessing patients following a fragility fracture",
        "body": "The management of patients following a fragility fracture depends on age, clinical risk factors, and whether the results of further investigation (such as DEXA) would influence management.<br /><br /><h5 class='notes-heading'>Patients \u2265 75 years of age</h5><br />Patients who've had a fragility fracture and are \u2265 75 years of age are generally presumed to have underlying osteoporosis and should usually be started on first-line therapy (an oral bisphosphonate), <span class=\"concept\" data-cid=\"552\">without the need for a DEXA scan</span>.<br /><ul><li>NICE guidance (NG212) states that a DEXA scan is not routinely required in this group if the result would not alter the treatment decision.</li><li><b>Treatment can be initiated based on clinical history alone</b>.</li></ul><br />The 2014 NOGG guidelines suggested treatment for all women over the age of 50 who had sustained a fragility fracture \u2013 <i>'although BMD measurement may sometimes be appropriate, particularly in younger postmenopausal women.'</i> However, more recent NOGG updates (2021/2023) now advise using FRAX thresholds to stratify risk and determine whether a DEXA is needed.<br /><br /><h5 class='notes-heading'>Patients < 75 years of age</h5><br />In patients under the age of 75 who sustain a fragility fracture:<br /><ul><li>A DEXA scan may be arranged to assess bone mineral density if the result is likely to influence treatment decisions.</li><li><b>Treatment may still be started without a DEXA if the clinical suspicion of osteoporosis is high</b>, particularly when a fragility fracture has occurred.</li><li>These results can be entered into a FRAX assessment (along with the history of fracture) to estimate ongoing fracture risk and guide long-term management.</li></ul><br />For example, a 79-year-old woman falls on to an outstretched hand and sustains a Colles' fracture (fracture of the distal radius). Given her age and the mechanism of injury, she is presumed to have underlying osteoporosis and is started on oral alendronate 70 mg once weekly. No DEXA scan is arranged, in line with current NICE guidance.",
        "notes_hash": "f0580da7f602032d04e52455ad097f4b",
        "knowledge_graph_node_id_link": 10843,
        "concept": "Start alendronate in patients >= 75 years following a fragility fracture, without waiting for a DEXA scan",
        "concept_percentile": "99",
        "concept_colour": "rgb(5,255,0)",
        "number_attempts": "5363",
        "up_votes": "41",
        "down_votes": "49",
        "column_array": [
            0,
            "267",
            "2759",
            "267",
            "520",
            "1550",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "<table style='width:100%'><tr><td>The National Osteoporosis Guideline Group</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_448\" data-linkid=\"448\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_448\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">9</span><button type=\"button\" style=\"\" id=\"link_dislike_448\" data-linkid=\"448\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_448\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">4</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.sheffield.ac.uk/NOGG/NOGG%20Guideline%202017.pdf\">NOGG Pocket Guide for Healthcare Professionals</a></td></tr></table>",
        "media": "",
        "comment_count": 18,
        "concepts_for_notes": {
            "552": {
                "concept_text": "Start alendronate in patients >= 75 years following a fragility fracture, without waiting for a DEXA scan",
                "concept_percentile": "99"
            }
        },
        "optimisation_reason": ""
    }
]